Items 1 ~ 8 of 2061, Page 1 of 258
New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health
IQcast Feature Aims to Predict the Likelihood of a Low Glucose Event Up to Four Hours in Advance
Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors
KEYTRUDA is the First Anti-PD-1 Approved in Japan for the First-Line Treatment of Advanced NSCLC as Both Monotherapy and in Combination with Chemother...
Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes
MK-3655 (formerly known as NGM313) is a proprietary, investigational agonistic antibody that selectively activates the β-Klotho/FGFR1c receptor comple...
Merck to Participate at the 37th Annual J.P. Morgan Healthcare Conference
Medtronic Chairman and CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - December 28, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will ...
LYNPARZA® (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Significantly Improved Objective Response Rate Compared to Chemotherapy in Platinum-Sensitive Relapsed Patients Who H...
Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patient...
LYNPARZA® (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70 Percent Compared to Placebo Following Response to Platinum-Bas...